Published in final edited form as:

Cancer Immunol Immunother. 2018 May ; 67(5): 835–841. doi:10.1007/s00262-018-2135-y.

Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor associated antigens

James A. Koziol¹, Haruhiko Imai², Liping Dai³, Jian-Ying Zhang^{3,4}, and Eng M. Tan¹

¹The Scripps Research Institute, La Jolla, California, USA

²Okudaira Clinic, Matsumoto, Japan

³Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China

⁴University of Texas at El Paso, Texas, USA

Abstract

Background—Multiple antigen miniarrays used for detecting autoantibodies to tumor-associated antigens (TAAs) can be a useful approach for cancer detection and diagnosis. We here address a very specific question: might there be autoimmune responses to TAAs which precede clinical detection of hepatocellular carcinoma (HCC) in HBV and HCV chronic liver disease patients under continuous medical surveillance and if so, could these anti-TAAs be added to the armamentarium of diagnostic tests?

Methods—We here examine the utility of a panel of 12 TAAs for the diagnosis of hepatocellular carcinoma (HCC). We derived a predictive rule for the presence of HCC based on a panel of 12 TAAs, from a cohort comprising 160 HCC patients and 90 normals. We then applied this rule to sequential anti-TAA data from a cohort of 17 HCC patients, from whom this information was available prior to diagnosis.

Results—The predictors (autoantibodies to HCC1, PI6, P53, P90 and survivin) indicated the presence of HCC prior to diagnosis in 16 of the 17 patients, at a median lead time of .75 year.

Conclusions—We believe these findings warrant further study of anti-TAA profiles as biomarkers for primary or early diagnosis of HCC.

Corresponding Author: James A. Koziol, Department of Molecular and Experimental Medicine, MEM290, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037 USA, koziol@scripps.edu.

Author contributions: Conception and design: James A. Koziol, Eng M. Tan. Development of methodology: Haruhiko Imai, Liping Dai, Jian-Ying Zhang, Eng M. Tan. Acquisition of data: Haruhiko Imai, Liping Dai, Jian-Ying Zhang, Eng M. Tan. Analysis and interpretation of data (computational and statistical analysis): James A. Koziol, Liping Dai, Eng M. Tan. Writing and revision of the manuscript: James A. Koziol, Liping Dai, Eng M. Tan. Review of the manuscript: James A. Koziol, Haruhiko Imai, Liping Dai, Jian-Ying Zhang, Eng M. Tan. Study supervision: Eng M. Tan.

Conflict of Interest: The authors declare that they have no conflicts of interest.

Compliance with ethical standards: Ethical approval and ethical standards: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. In particular, this study was approved by the Institutional Review Board of the University of Texas at El Paso and collaborating institutions. This study does not contain any studies with animals performed by any of the authors.

Keywords

autoantibody profiles; tumor-associated antigens; classification; hepatocellular carcinoma

1. Introduction

In 2012, liver cancer was the fifth most common cancer in men, and the ninth in women, in terms of estimated incidence worldwide [1]. It is a pernicious disease, and is the second most common cause of death from cancer worldwide. The prognosis for liver cancer is quite poor, with overall ratio of mortality to incidence of about .95. In the United States, one year survival is less than 40%, and 5 year survival is less than 15% [2, 3]. Definitive diagnosis is typically achieved with either CT scanning or MRI, but these modalities may well be too costly or unavailable in many regions with high prevalence of liver cancer. Techniques for early detection and diagnosis that involve “liquid biopsy” [4] may be viable alternatives in these situations, and our study is an initial step toward this goal.

A long-standing research interest of ours has been the investigation of the utility of autoantibody profiles to tumor-associated antigens (TAAs) for discriminating between cancer patients and controls [5, 6, 7]. We found that these multiple antigen miniarrays could provide accurate tools for cancer detection and diagnosis, and suggested that performance of the miniarrays might be enhanced by other combinations of TAAs appropriately selected for different cancer cohorts. From our previous studies, we had amassed a collection of serial serum samples from individuals with HBV and HCV-associated liver diseases who developed hepatocellular carcinoma (HCC) and came from liver disease clinics in three different countries, China, Japan and South Korea. This presented us the opportunity to ask the important, clinically relevant question: Would these patients develop autoantibodies to tumor-associated antigens prior to clinically detectable HCC? We address this question directly in the present paper, where we examine the utility of an expanded panel of 12 autoantibody profiles for cancer diagnosis of HCC, based on serum samples from newly-diagnosed HCC patients and normal controls. In particular, we hypothesized that a predictive tool for HCC derived from a panel of TAAs could serve as an early warning system for HCC.

2. Materials and Methods

2.1 Sera samples

In all, serum samples from 177 HCC patients and 90 normal controls were amassed, as follows. Sera from 76 patients with HCC from Xiamen in China were obtained from the serum bank of the Cancer Autoimmunity Research Laboratory at the University of Texas (El Paso, Texas, USA), which were originally provided by a collaborator in Sun Yat-sen University (Guangzhou, China). 84 HCC patients' sera were collected from South Korea (Yonsei University, Seoul), and 17 from Japan (Shinshu University Hospital, Matsumoto). Ninety normal human sera (NHS) were originally obtained from the serum bank of the Autoimmune Disease Center at the Scripps Research Institute (La Jolla, CA, USA). These controls were actively working individuals who had no obvious signs or symptoms of viral

hepatitis or any other forms of hepatitis. All cancer patients were diagnosed according to established criteria; their serum samples were collected at the time of initial cancer diagnosis, when the patients had not received treatment with any chemotherapy or radiation therapy. In addition, sera from the 17 patients from Japan had also been collected periodically for varying lengths of time prior to diagnosis. This study was approved by the Institutional Review Board of the University of Texas at El Paso and collaborating institutions.

2.2 Expression and purification of recombinant proteins

The twelve antigens HCC1, IMP1, Koc, MDM2, NPM1, p16, p53, p62, p90, RalA, survivin, and 14-3-3 ζ , were expressed as recombinant proteins. The sources of the 12 genes' cDNA clones were described in detail in a previous study [7]. cDNAs of HCC1, IMP1, Koc, MDM2, NPM1, p53, p62, survivin, RalA, survivin, and 14-3-3 ζ genes were subcloned into pET28a vector producing a fusion protein with NH-terminal 6 $\times$ histidine and T7 epitope tags [8-14]. The recombinant proteins expressed in *Escherichia coli* BL21 (DE3) were purified using nickel column chromatography. cDNAs of p16 and p90 were subcloned into pEGX vector expressing protein with glutathione S transferase (GST) fusion partner. The GST gene fusion system was utilized for the expression and purification of p16 and p90 recombinant protein [15,16]. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue staining were utilized to establish that expression products with expected molecular masses were produced. In addition, Western blotting analysis was used to confirm that the bands seen in SDS-PAGE were reactive with reference antibodies.

2.3 Enzyme-linked immunosorbent assay (ELISA)

Autoantibodies against 12 TAAs were determined by ELISA using purified recombinant proteins as described in our previous study [7]. Briefly, the recombinant proteins were coated into 96 well plates at a concentration of 0.5 μ g/mL. The human serum samples, diluted 1:200, were incubated in the antigen-coated wells for 90 min, followed by horseradish peroxidase (HRP)-conjugated goat anti-human IgG used as the secondary antibody at 1:4,000 dilution. The substrate 2,2'-azino-bis (3-ethylbenzothiazoline- 6-sulfonic acid) diammonium salt (ABTS) (Sigma, St. Louis, MO, USA) was used as the detecting agent. The optical density (OD) value was read at 405nm for each well. Each sample was tested in duplicate, and the average OD value was used for all analyses. Each run of ELISA included 8 normal human sera (NHS), representing a range of absorbance above and below the mean of the original 90 NHS, and the average OD value of 8 NHS was used to normalize all absorbance values to the standard mean of the entire 90 normal samples. All of the sera with positive results in ELISA were verified by Western Blotting with purified recombinant proteins, as described previously [7].

2.4 Statistical methods

Logistic regression was used to derive a predictor rule for presence or absence of HCC, based on anti-TAA levels in the set of 90 normals and 160 cases (84 from South Korea, 76 from China). In this regard, the minimum Bayes information criterion (BIC [17]) was used to identify the optimal subset of TAAs for the logistic regression classifier, using an all

possible subsets algorithm. [The BIC is based on the likelihood function, but with a penalty for overfitting.] This subset included autoantibodies to HCC1, P16, P53, P90, and survivin.

Operating characteristics of the logistic regression classifier based on these 5 TAAs were derived from 1000 cross-validation runs for 10-fold cross-validation, and also leave one out cross-validation (LOOCV). For each 10-fold cross-validation run, the entire data set was randomly divided into 10 equally sized subsets, and the classifiers were trained on 9 subsets and tested on the remaining subset (the validation subset). This cross-validation was repeated 9 additional times (so that each of the 10 subsets served as the validation subset once only), and the results on the test sets combined to calculate the predictive accuracy and error rates of each classifier. We initially performed 10-fold cross-validation on the original dataset of 250 individuals. We then refined the cross-validation procedure, by stratifying the random division (into 10 subsets) separately by location (90 normals, 76 cases from China, 84 cases from South Korea). For LOOCV, each observation in the training sample is omitted in turn, and the logistic classifier is trained on the remaining observations; this classifier is used to predict the status (class) of the omitted observation. The LOOCV estimates of the classification rates are based on the fractions of the omitted observations that are correctly classified.

The dataset comprising the anti-TAA data from the 90 normals and 160 HCC cases (76 from China, 84 from South Korea) was used solely to derive the predictor rule for HCC. We then took the prediction rule from the logistic regression classifier, and applied it to the data consisting of the sequential anti-TAA levels in 17 HCC patients from Japan, the goal here being to determine whether, or when, HCC would be suspected or considered in these patients based on the prediction rule, prior to “official” diagnosis of HCC.

There were no missing data in either the 250 subject dataset or the sequential data from Japan. Descriptive statistics were calculated in SPSS v22 (IBM Corp., 2013), and the logistic regression analyses were undertaken in JMP 11.0 (SAS Institute Inc., 2013) and Matlab R2014b (The MathWorks Inc., 2014).

3. Results

3.1 Descriptive statistics

Descriptive statistics relating to anti-TAA levels in the first dataset (160 HCC patients, and 90 controls) are given in Table 1. In general, autoantibody levels are not normally distributed in either cases or controls, but tend to be characterized by positive skewness and heavy kurtosis. In addition, anti-TAA levels tend to be higher in cases than controls, with varying degrees of overlap. This can be seen in Supplementary Figure 1, which depicts dual histograms with each TAA, for the patients and the controls. Generally, anti-TAA levels appear to be somewhat elevated in cases relative to controls, but occasional extreme values might well distort the perceived separation between the cohorts. Although discrimination between cases and controls on the basis of some of the anti-TAAs appears feasible, it is interesting that occasionally, anti-TAA levels in a few of the controls are consistent with a diagnosis of HCC [e.g., 14-3-3 ζ , P16, P90]; and, with RalA, anti-TAA levels are noticeably less in some cases than in the controls.

3.2 Classifier: First dataset

As described above, logistic regression was used to derive a classifier for HCC vs. normal from the dataset comprising 90 normals and 160 HCC cases (76 from China, 84 from South Korea). The optimal classifier, based on a minimum Bayes information criterion, is based on 5 of the 12 TAAs, namely, HCC1, P16, P53, P90, and survivin. In order to implement the logistic regression classifier for an individual, a numerical score for that individual is calculated, based on that individual's OD values for those TAAs:

$$score = -3.95 + 10.7 * HCC1 - 4.14 * P16 + 13.95 * P53 + 28.92 * P90 + 6.48 * survivin.$$

Then, the classification rule is:

if $score > 0$, the individual is classified as having HCC

if $score < 0$, the individual is classified as not having HCC

The operating characteristics of the classifier rule based on these 5 TAAs were assessed by cross validation, as detailed in the methods. Interestingly, operating characteristics for leave one out cross-validation (LOOCV) and both methods of 10-fold cross-validation were virtually identical: sensitivity of the 5-TAA classifier was estimated as .880 from the original 10-fold cross-validation compared to .881 with stratified 10-fold cross-validation and LOOCV; specificity was estimated as .841 with the original 10-fold cross-validation compared to .833 with both stratified 10-fold cross-validation and LOOCV.

3.3 Classifier: Sequential data

As noted previously, there were sequential anti-TAA data available for 17 HCC patients, prior to diagnosis of HCC. The classifier rule was applied to the sequential data, the purpose being to identify the earliest preclinical stage at which the presence of HCC would be indicated with the TAA classifier rule. In 12 patients (Figure 1), HCC would have been indicated (i.e., $score > 0$) at the earliest time at which anti-TAA values were recorded; in 4 patients (Figure 2), HCC would have first been indicated subsequent to the initial time of availability of anti-TAA levels, but prior to time of diagnosis; and in 1 patient (Figure 3), the classifier would not have indicated presence of HCC prior to time of diagnosis. Among the 16 patients for whom HCC was flagged by the classifier, the time when flagged ranged from .1 year to 1.2 years, median .75 year (mean = .72 year, standard deviation = .31 year).

4. Discussion

In a previous study [5], we reported that multiple antigen miniarrays could serve as useful tools for cancer detection and diagnosis. The utility of autoantibodies in cancer diagnosis was demonstrated there, because of the typical absence of elevated or depressed levels of particular autoantibodies in normal individuals. In addition, we had previously proposed [18, 19] that autoantibodies might successfully be used as indicators of aberrant cellular mechanisms in tumorigenesis. In the oncologic setting, we further suggested that autoantibody panels might be adopted as predictive markers, that is, they might provide early warning of the onset of cancer.

The current study investigates this concept: we examined the utility of an expanded panel of 12 anti-TAA profiles for diagnosis of hepatocellular carcinoma. We first derived a classifier for HCC from a training set of 160 HCC patients and 90 normals, based on 5 of the 12 TAAs in our panel; then, using this classifier on a test set comprising sequential data from 17 HCC patients prior to diagnosis, we found that the classifier signals HCC in 16 of the 17 subjects, at a median of 9 months prior to diagnosis. This finding raises the notion that some autoantibodies may be detectable before overt signs and symptoms of HCC and might serve as an early warning system of malignant conversion in high risk patients such as those with HBV/HCC hepatitis. Early detection of HCC should lead to improved survival rates, since tumors should be smaller and at an earlier stage in tumor evolution, and metastatic spread minimized, leading to improvements in overall survival [20]. Nevertheless, incorporation of a panel of TAAs into a systematic program of HCC surveillance for high-risk patients ought to be preceded by evaluation of the panel with a defined disease control group (e.g., autoimmune liver disease, obstructive biliary disease, cirrhosis) as comparator.

We believe a strength of our approach is the incorporation of a multivariate classifier for the presence of HCC. We have shown in previous studies [e.g., 5] that panels of TAAs provide improved operating characteristics [e.g., sensitivity, specificity] over individual TAAs for diagnosis, and reliance on fixed cutoffs for positivity in ELISAs [e.g., mean + 2 standard deviations for ODs] does not derive full information from these assays [5, 21]. [From a statistical perspective, judicious combinations of variables tend to outperform individual variables as classifiers; and, one typically derives more information from a “continuous” variable than from a “dichotomous” version of it.]

Nevertheless, our study has limitations. From a statistical perspective, our classifier could be improved on. Our use of logistic regression as a comparator is motivated by its ease of interpretation, and relatively good performance in our previous studies; as well, both cases and controls in our training set are numerous and not totally unbalanced, and our explanatory variables are not highly correlated. Still, classifiers based on other criteria or methods might enjoy gains in performance. For example, we could have used a different criterion to BIC for variable selection. In this regard, we did examine classifiers chosen on the basis of Akaike's information criterion: this resulted in an expansion of the number of variables in our classifier [while maintaining the core group of HCC1, P16, P53, P90, and surviving], but with no noticeable improvements in performance. Also, in the current setting we have previously investigated classifiers based on restricted Boltzmann machines [22], and were encouraged by their relatively good performance as classifiers. Perhaps more pertinent would be optimal selection of TAAs for any classification rule: we might expect improvements in the operating characteristics of any classifier through inclusion of judiciously selected TAAs that are not part of our panel.

We acknowledge that our study is retrospective, and nothing is known about the clinical characteristics of the subjects in either the original dataset of 250 subjects (China, South Korea, US) or the sequential dataset from Japan. Serum samples were provided anonymously, with no additional information, reflective of the national laws and confidentiality and ethical standards of the institutions from which the samples were obtained. Furthermore, our normal controls were not matched for age, gender, or ethnicity

with the cases, though anti-TAA levels should be negligible among normal individuals regardless of demographics. Still, it is quite possible that clinical or demographic information could have profitably been incorporated into the classifier, or perhaps identification of high-risk subjects for whom frequent monitoring of anti-TAA levels would be warranted.

In addition, a reviewer has commented that “it would be important to have as controls viral hepatitis patients that do not progress to malignancy. The effects of hepatitis viruses, especially HBV, are well known and it is important to determine what is malignancy-related and what is virus-related, with an appreciation that there may be an overlap in these distinctions.” We agree with this assessment, which is congruent with our objective of drawing interest to the possibilities of utilizing anti-TAAs as tools for early detection of conversion from chronic liver disease to HCC.

Given our study limitations, we caution against interpreting this study to be a conclusive validation of the clinical value or utility of TAA panel-based testing for HCC. Nevertheless, our positive finding that some autoantibodies to TAAs do antedate clinically overt HCC provides some justification for well-controlled prospective studies with complete demographic and clinical data so as to either confirm or invalidate our observations. We therefore hope to raise interest in such prospective studies by clinics in countries with high prevalence of HBV- and HCV- associated liver diseases. We of course would be happy to encourage such studies by supplying cDNA clones encoding TAAs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We wish to acknowledge the generous donation of HCC sera from Dr. David Lee.

Funding: The authors would like to acknowledge funding received from the National Institutes of Health: 1 PO1 HL119165 (Koziol).

References

1. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, DM., Forman, D., Bray, F. IARC Cancer Base No. 11; Lyon, France: International Agency for Research on Cancer; 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. Internet Available from: <http://globocan.iarc.fr> [accessed on 17 October 2015]
2. [accessed on 17 October 2015] National Cancer Institute, Surveillance, Epidemiology, and End Results Program, Fast Stats, SEER Mortality. Available from <http://seer.cancer.gov/faststats>
3. El-Serag H, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go? Hepatology. 2014; 60:1767-. [PubMed: 24839253]
4. Pantel K, Alix-Panabières C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Research. 2013; 73:6384–6388. [PubMed: 24145355]
5. Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, Chan EK, Tan EM. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res. 2003; 9:5120–6. [PubMed: 14613989]

6. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. *Cancer Epidemiol Biomarkers Prev.* 2003; 12:136–143. [PubMed: 12582023]
7. Dai L, Ren P, Liu M, Imai H, Tan EM, Zhang JY. Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma. *Clin Immunol.* 2014; 152:127–139. [PubMed: 24667685]
8. Zhang JY, Chan EKL, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. *J Exp Med.* 1999; 189:1101–1110. [PubMed: 10190901]
9. Müller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Büchler M, Beger HG, Vila MR, Adler G, Gress TM. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. *Oncogene.* 1997; 14:2729–2733. [PubMed: 9178771]
10. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. *Mol Cell Biol.* 1999; 19:1262–1270. [PubMed: 9891060]
11. Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. *J Clin Invest.* 1993; 92:2419–2426. [PubMed: 8227358]
12. Liu M, Varela-Ramirez A, Li J, Dai L, Aguilera RJ, Zhang JY. Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma. *Oncology Reports.* 2015; 33:2245–2252. [PubMed: 25779011]
13. Liu M, Zheng SJ, Chen Y, Li N, Ren PF, Dai LP, Duan ZP, Zhang JY. Autoantibody response to murine Double Minute 2 Protein in immunodiagnosis of hepatocellular carcinoma. *J Immunol Res.* 2014; 2014:906532. [PubMed: 24955377]
14. Liu M, Liu X, Ren P, Li J, Zheng SJ, Chen Y, Duan ZP, Li N, Zhang JY. A cancer-related protein 14-3-3 ζ is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma. *Tumor Biology.* 2014; 35:4247–4256. [PubMed: 24390614]
15. Looi K, Megliorino R, Shi FD, Peng XX, Chen Y, Zhang JY. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. *Oncol Rep.* 2006; 16:1105–10. [PubMed: 17016600]
16. Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC, Zhang JY. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. *J Proteome Res.* 2008; 7:4004–12. [PubMed: 18672925]
17. Schwarz G. Estimating the dimension of a model. *Annals of Statistics.* 1978; 6:461–464.
18. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. *J Clin Invest.* 2001; 108:1411–1415. [PubMed: 11714730]
19. Tan EM, Zhang JY. Autoantibodies to tumor-associated antigens: Reporters from the immune system. *Immunol Rev.* 2008; 222:328–340. [PubMed: 18364012]
20. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: A Meta-analysis. *PloS Med.* 2014; 11:e1001624.
21. Dai L, Tsay JC, Li J, Yie TA, Munger JS, Pass H, Rom WN, Zhang Y, Tan EM, Zhang JY. Autoantibodies against tumor-associated antigens in the early detection of lung cancer. *Lung Cancer.* 2016; 99:172–179. [PubMed: 27565936]
22. Koziol JA, Tan EM, Dai L, Ren P, Zhang JY. Restricted Boltzmann machines for classification of hepatocellular carcinoma. *Computational Biology Journal.* 2014; 2014:Article ID 418069.

Abbreviations

BIC	Bayes information criterion
ELISA	enzyme-linked immunosorbent assay
LOOCV	leave one out cross validation

NHS normal human ser

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.

Classification scores for 12 HCC patients with sequential anti-TAA data, prior to time of diagnosis (time = 0). A score > 0 would indicate presence of HCC. A. In these 12 patients, the classification score would have indicated presence of HCC at initial evaluation.

Figure 2. Classification scores for 4 HCC patients with sequential anti-TAA data, prior to time of diagnosis (time = 0). A score > 0 would indicate presence of HCC. In these 4 patients, the classification score would have indicated presence of HCC subsequent to initial evaluation, but prior to formal diagnosis.

Figure 3. Classification scores for 1 HCC patient with sequential anti-TAA data, prior to time of diagnosis (time = 0). A score > 0 would indicate presence of HCC. In this patient, the classification score would not have indicated presence of HCC prior to time of diagnosis.

Table 1

Descriptive Statistics for Serum Autoantibody Levels to 12 Tumor-Associated Antigens.

A. Cases (N=160)											
	14-3-3 ζ	HCC1	IMP1	KOC	MDM2	NPM1	P16	P53	P62	P90	survivin
Minimum	0.000	0.000	0.028	0.003	0.002	0.007	-0.010	0.000	0.000	0.001	0.027
Maximum	0.493	0.580	4.031	2.193	0.602	1.706	1.166	3.743	3.347	0.660	2.760
Range	0.493	0.580	4.003	2.190	0.600	1.699	1.176	3.743	3.347	0.659	2.733
Interquartile Range	0.069	0.093	0.120	0.080	0.080	0.222	0.165	0.095	0.184	0.089	0.128
Median	0.082	0.099	0.140	0.088	0.127	0.163	0.184	0.114	0.226	0.124	0.149
Arithmetic Mean	0.107	0.123	0.221	0.126	0.153	0.256	0.235	0.176	0.274	0.140	0.203
Standard Deviation	0.083	0.099	0.400	0.193	0.105	0.257	0.176	0.347	0.315	0.087	0.257
Skewness	2.305	1.757	6.811	8.183	1.968	2.803	2.060	8.276	6.477	2.411	6.999
Kurtosis	7.422	3.880	55.932	83.437	4.436	10.581	6.224	77.763	58.267	9.838	63.834

B. Controls (N=90)											
	14-3-3 ζ	HCC1	IMP1	KOC	MDM2	NPM1	P16	P53	P62	P90	survivin
Minimum	0.012	0.004	0.024	0.012	0.005	0.000	0.017	0.014	0.015	0.011	0.018
Maximum	0.260	0.236	0.383	0.271	0.217	0.616	0.685	0.224	0.347	0.452	0.376
Range	0.248	0.232	0.359	0.259	0.212	0.616	0.668	0.210	0.332	0.441	0.358
Interquartile Range	0.038	0.044	0.071	0.039	0.054	0.083	0.111	0.033	0.090	0.031	0.044
Median	0.060	0.043	0.090	0.047	0.076	0.057	0.110	0.056	0.106	0.042	0.061
Arithmetic Mean	0.067	0.055	0.110	0.058	0.078	0.099	0.142	0.059	0.120	0.053	0.075
Standard Deviation	0.037	0.045	0.068	0.051	0.043	0.114	0.107	0.029	0.069	0.049	0.057
Skewness	2.144	1.997	1.822	2.497	0.632	2.466	2.199	2.219	0.907	6.177	3.479
Kurtosis	7.781	4.845	4.086	7.146	0.299	6.789	7.157	10.689	0.621	48.773	16.097

Notes

14-3-3 ζ : tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta

HCC1: RNA binding motif protein 39

IMP1: insulin like growth factor 2 mRNA binding protein 1

KOC: insulin like growth factor 2 mRNA binding protein 3

MDM2: MDM2 proto-oncogene

NPM1: nucleophosmin

P16/CDKN2A: cyclin dependent kinase inhibitor 2A

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

p53/TP53: tumor protein p53
p62/IGF2BP2: insulin like growth factor 2 mRNA binding protein 2
p90/CIP2A: KIAA1524
RaiA: RAS like proto-oncogene A
survivin: baculoviral IAP repeat-containing protein 5.1-A-like